Share on StockTwits

Jazz Pharmaceuticals plc - (NASDAQ:JAZZ) CEO Bruce C. Cozadd unloaded 5,000 shares of the company’s stock in a transaction that occurred on Tuesday, July 8th. The stock was sold at an average price of $155.00, for a total transaction of $775,000.00. Following the sale, the chief executive officer now directly owns 597,067 shares of the company’s stock, valued at approximately $92,545,385. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Several analysts have recently commented on the stock. Analysts at FBR Capital Markets reiterated a “top pick” rating on shares of Jazz Pharmaceuticals plc – in a research note on Wednesday, July 2nd. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Jazz Pharmaceuticals plc – in a research note on Friday, June 20th. They now have a $157.00 price target on the stock. Finally, analysts at JMP Securities initiated coverage on shares of Jazz Pharmaceuticals plc – in a research note on Tuesday, June 17th. They set an “outperform” rating and a $179.00 price target on the stock. Five equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $168.60.

Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) traded down 1.43% during mid-day trading on Thursday, hitting $152.49. 870,407 shares of the company’s stock traded hands. Jazz Pharmaceuticals plc – has a 1-year low of $70.33 and a 1-year high of $176.60. The stock’s 50-day moving average is $147.3 and its 200-day moving average is $144.2. The company has a market cap of $9.057 billion and a price-to-earnings ratio of 117.64.

Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) last announced its earnings results on Thursday, May 8th. The company reported $1.61 earnings per share for the quarter, missing the analysts’ consensus estimate of $1.79 by $0.18. The company had revenue of $247.00 million for the quarter, compared to the consensus estimate of $254.86 million. During the same quarter last year, the company posted $1.37 earnings per share. Jazz Pharmaceuticals plc -’s revenue was up 25.8% compared to the same quarter last year. On average, analysts predict that Jazz Pharmaceuticals plc – will post $8.07 earnings per share for the current fiscal year.

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.